4 109

Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells

Authors
 Jung-Hyun Kim  ;  Minjung Song  ;  Geun-Ho Kang  ;  Eung-Ryoung Lee  ;  Hye-Yeon Choi  ;  Chung Lee  ;  Jin-Hoi Kim  ;  Youngsoo Kim  ;  Bon-Nyeo Koo  ;  Ssang-Goo Cho 
Citation
 Leukemia Research, Vol.36(9) : 1157-1164, 2012 
Journal Title
 Leukemia Research 
ISSN
 0145-2126 
Issue Date
2012
Abstract
Imatinib mesylate, a Bcr/Abl tyrosine kinase inhibitor, is widely used in treating chronic myeloid leukemia. However, drug-resistance of leukemia cells becomes an emergent problem. Herein, various flavonoids were screened for applicability in leukemia treatment, and 3-hydroxyflavone (3-HF) was found to be most effective in reducing cancer cell viability. The combination of 3-HF and imatinib mesylate resulted in significant apoptotic cell death in imatinib mesylate-resistant leukemia cells. Combined treatment resulted in apparent activation of caspases and decrease of the oncoprotein phosphor-Bcr/Abl in leukemia cells. Our results suggest that this combined treatment is beneficial in imatinib mesylate-resistant chronic myelogenous leukemia.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/91401
Full Text
http://www.sciencedirect.com/science/article/pii/S0145212612002433
DOI
10.1016/j.leukres.2012.05.018
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Anesthesiology and Pain Medicine (마취통증의학교실)
Yonsei Authors
구본녀(Ku, Bon Nyo)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse